HoldsUp

Eran Elinav

Weizmann Institute of Science and German Cancer Research Center

Eran Elinav, MD, PhD, is a professor of immunology and principal investigator at the Weizmann Institute of Science and the German Cancer Research Center, where he co-directs the Personalized Nutrition Project. His research focuses on host-microbiome interactions and how gut bacteria impact human health and disease. His published work investigates topics including personalized nutrition, dietary assessment, mucosal immunity, metabolic disorders, and cancer-microbiome interactions.

53 claims checked on air: 2 context 6 overstated 42 supported 3 unverified

What they said on air - citing their own research

5 citing their own research

0:39:52supportedmoderatetheir own paperDr. Eran Elinav on Microbiome Insights into Personalized Res

A preliminary small-scale study found that personalized glycemic responses to saccharin in humans occurred and were transferable to germ-free mice via microbiome transfer.

"So with the artificial sweeteners, as part of the original study, we we published a very preliminary small-scale study suggesting that personalized responses um to uh saccharin in humans do occur, and it could be even transferred upon microbiome transfers from human into humans into germ-free mice." (said at 0:39:52)

The speaker accurately describes published findings from their research group (Suez et al., 2014 in Nature, followed by a randomized controlled trial in 2022 in Cell). In the original preliminary human study, healthy volunteers consuming saccharin showed personalized glycemic responses (some developing impaired glucose tolerance while others did not). Fecal microbiota transplantation from human responders into germ-free (gnotobiotic) mice transferred the impaired glycemic phenotype, whereas transfer from non-responders did not.

0:42:27overstatedhightheir own paperDr. Eran Elinav on Microbiome Insights into Personalized Res

Over 100,000 individuals have been tested on thousands of food components and food additives through the Personalized Nutrition pipeline.

"and we've tested thousands of them in in over 100,000 people that underwent our personalized nutrition uh pipeline or project—we found that people distinctly react to foods or food components or food additives, even if they're exposed to the same exact amounts of the same exact component." (said at 0:42:27)

Published peer-reviewed literature from the Personalized Nutrition Project supports the core premise that individuals demonstrate distinct, personalized glycemic and metabolic responses when exposed to identical foods or food additives (PMID: 26590418, PMID: 35987213). However, claiming that over 100,000 individuals were tested across thousands of food components within this research pipeline overstates the cohort sizes published in peer-reviewed studies. The primary study establishing the Personalized Nutrition Project evaluated continuously monitored glycemic responses to 46,898 meals in an 800-person cohort with an independent 100-person validation cohort (PMID: 26590418). Specific clinical trials investigating food additives (such as non-nutritive sweeteners) were conducted in cohorts of 120 participants (PMID: 35987213).

1:36:11supportedvery lowtheir own paperDr. Eran Elinav on Microbiome Insights into Personalized Res

Interactions between the microbiome and host generate compounds that drive the obesity that develops after smoking cessation.

"we've recently published another study focusing on a peculiar type of obesity that develops after cessation of cigarette smoking. And to make a long story short, we found a similar cooperation between the microbiome and the host in generating compounds that could drive this obesity phenomenon after smoking cessation." (said at 1:36:11)

A 2021 study by the speaker's group published in Nature demonstrated that gut microbiota changes driven by cigarette smoke exposure and cessation promote smoking-cessation-induced weight gain in mouse models. The mechanism involved concerted host and microbiome metabolic cooperation, specifically shunting dietary choline to dimethylglycine (driving increased energy harvest) alongside the depletion of N-acetylglycine. Because the primary causal mechanism was established in animal models with only preliminary observational human cohort data, the certainty of evidence for human clinical outcomes remains very low.

1:39:14supportedlowtheir own paperDr. Eran Elinav on Microbiome Insights into Personalized Res

Cigarette-related chemicals reach the systemic circulation, penetrate the gut, and alter the composition and function of the microbiome.

"when we measure what it does to the microbiome, we were intrigued to find that many cigarette-related chemicals not only reach the systemic circulation, but they actually penetrate the gut and they impact the microbiome towards a disturbed composition and function." (said at 1:39:14)

Published experimental research in animal models, supported by preliminary human observational data, confirms that inhaled cigarette smoke-derived chemicals enter the systemic circulation, penetrate the gastrointestinal tract, and drive compositional and functional changes (dysbiosis) in the gut microbiome. A landmark 2021 study showed that an intestinal influx of cigarette-smoke-related metabolites directly alters gut microbial composition and function, modulating host metabolism and energy harvest.

1:41:20supportedmoderatetheir own paperDr. Eran Elinav on Microbiome Insights into Personalized Res

A randomized clinical trial demonstrated that a personalized, data-driven diet outperformed the American Diabetes Association-recommended diet in controlling blood glucose in pre-diabetic individuals.

"tested by us in different contexts, including recently in a long-term randomized human trial which compared this data-driven personalized approach to the gold standard American Diabetes Association-recommended diet. And we've quite convincingly showed that this personalized, science-driven approach was outperforming the current one-size-fits-all diet in a large group of pre-diabetic individuals" (said at 1:41:20)

A 2021 randomized controlled trial (Ben-Yacov et al., published in Diabetes Care) evaluated 225 adults with prediabetes assigned to either a personalized postprandial-targeting (PPT) diet driven by machine-learning algorithms or a standard Mediterranean diet (an ADA-recommended dietary pattern). Over a 6-month intervention and subsequent 6-month follow-up, the personalized diet led to significantly greater reductions in daily time spent with glucose >140 mg/dL and greater reductions in HbA1c compared to the Mediterranean diet.

Fact-checked episodes

Publications